Strong Q1 Results#
Edwards Lifesciences, a prominent medical device company, has reported impressive first-quarter results for 2026. The company achieved sales of $1.649 billion, surpassing Wall Street's expectations by $52 million. Additionally, it posted adjusted earnings per share (EPS) of $0.78, which is five cents higher than analysts had predicted.
Key Financial Metrics#
The company's strong performance is evident in its gross profit margin of 78% and an 11.55% increase in revenue over the past year. Notably, sales from the Transcatheter Aortic Valve Replacement (TAVR) segment reached $1.197 billion, exceeding the consensus estimate of $1.164 billion by $33 million. Meanwhile, sales from the company's other segment, TMTT, totaled $173 million, which is about $8 million above expectations.
Growth Outlook#
Edwards Lifesciences has raised its sales guidance for 2026, now projecting a year-over-year growth rate of 9%-11%. This optimistic outlook is driven by a stronger growth forecast for TAVR, which is now expected to grow at a rate of 7%-9% annually, up from the previous estimate of 6%-8%. The company also confirmed that timelines for TAVR National Coverage Determination (NCD) remain on track, with a draft decision memo anticipated by June 15.
Analyst Insights#
Following these results, BTIG has raised its price target for Edwards Lifesciences from $98 to $100 while maintaining a Buy rating. This new target is based on a price-to-earnings (P/E) ratio of 29 applied to the company's adjusted EPS forecast for the next 12-24 months. Currently, the stock trades at a P/E ratio of 44.04, indicating it may be slightly undervalued. Analysts' price targets for the stock range from $84 to $110, reflecting a range of perspectives on its future performance.